Semaglutide Win in HFpEF With Obesity Regardless of LVEF

Were the GLP-1 receptor agonist drug's apparent benefits in STEP-HFpEF due solely to weight loss or additional mechanisms? The trial offers a clue, experts say.
Medscape Medical News